Want to see DYN full AI Analyst Report?
Top Page
Dyne Therapeutics
(NASDAQ:DYN)
Select Model
Select Model
Rating:59Neutral
Price Target:
$26.00
▲(6.38% Upside)
Action:Reiterated
Date:07/30/26
Overall score is held back primarily by weak financial performance: no revenue and substantial, worsening cash burn and losses. Offsetting factors include a technically strong trend (price above key moving averages) and several positive corporate catalysts—Priority Review for DYNE-251 and a large financing that extends cash runway—supporting the medium-term outlook despite dilution and ongoing loss-making operations.
Positive Factors
Proprietary FORCE delivery platform
Dyne’s FORCE platform provides a durable technical moat by enabling targeted delivery to muscle and related tissues. Platform-level delivery differentiates multiple candidates, supports pipeline expansion across neuromuscular indications, and underpins repeatable partnerships and licensing revenue opportunities.
Negative Factors
High cash burn and sustained losses
Dyne remains pre-revenue with very large, persistent cash burn, meaning continued reliance on external financing. Over time this forces management to prioritize programs by capital efficiency, raises execution risk if funding gaps occur, and limits margin visibility until commercial sales emerge.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary FORCE delivery platform
Dyne’s FORCE platform provides a durable technical moat by enabling targeted delivery to muscle and related tissues. Platform-level delivery differentiates multiple candidates, supports pipeline expansion across neuromuscular indications, and underpins repeatable partnerships and licensing revenue opportunities.
Read all positive factors
Dyne Therapeutics (DYN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.70B
Dividend YieldN/A
Average Volume (3M)2.58M
Price to Earnings (P/E)―
Beta (1Y)1.79
Revenue GrowthN/A
EPS Growth13.71%
CountryUS
Employees258
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.33
Shares Outstanding186,746,430
10 Day Avg. Volume3,130,021
30 Day Avg. Volume2,584,936
Financial Highlights & Ratios
PEG Ratio-1.90
Price to Book (P/B)2.58
Price to Sales (P/S)0.00
P/FCF Ratio-6.20
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$40.27Price Target Upside64.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-3.46
Revenue Forecast (FY)N/A
Dyne Therapeutics Business Overview & Revenue Model
Company Description
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, ...
How the Company Makes Money
Dyne Therapeutics primarily makes money through a mix of (1) collaboration/partnering revenue and (2) financing, because it is a clinical-stage company without broadly marketed commercial products.
1) Collaboration and partnership revenue: When D...
Dyne Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
63
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.07M | -2.05M | -2.24M | -2.46M | 0.00 | 0.00 |
| EBITDA | -495.35M | -437.97M | -315.18M | -233.48M | -163.50M | -148.20M |
| Net Income | -519.41M | -446.21M | -317.42M | -235.94M | -168.10M | -149.29M |
Balance Sheet | ||||||
| Total Assets | 994.01M | 1.19B | 691.23M | 165.08M | 306.32M | 425.66M |
| Cash, Cash Equivalents and Short-Term Investments | 898.48M | 1.11B | 642.27M | 123.10M | 256.01M | 376.57M |
| Total Debt | 19.87M | 20.28M | 23.99M | 27.41M | 30.48M | 32.64M |
| Total Liabilities | 291.86M | 214.83M | 61.40M | 73.79M | 53.96M | 57.47M |
| Stockholders Equity | 702.15M | 972.13M | 629.84M | 91.29M | 252.36M | 368.20M |
Cash Flow | ||||||
| Free Cash Flow | -499.22M | -405.13M | -294.75M | -188.89M | -156.71M | -123.18M |
| Operating Cash Flow | -477.82M | -403.21M | -292.37M | -188.16M | -153.65M | -119.56M |
| Investing Cash Flow | -44.17M | -28.75M | -204.08M | 83.31M | 87.20M | -137.89M |
| Financing Cash Flow | 713.47M | 890.31M | 809.89M | 54.32M | 37.39M | 157.82M |
Dyne Therapeutics Technical Analysis
Positive
24.44
Price Trends
21.40
Positive
19.83
Positive
19.21
Positive
Market Momentum
1.16
Positive
65.41
Neutral
81.86
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DYN, the sentiment is Positive. The current price of 24.44 is above the 20-day moving average (MA) of 24.35, above the 50-day MA of 21.40, and above the 200-day MA of 19.21, indicating a bullish trend. The MACD of 1.16 indicates Positive momentum. The RSI at 65.41 is Neutral, neither overbought nor oversold. The STOCH value of 81.86 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DYN.
Dyne Therapeutics Risk Analysis
Dyne Therapeutics disclosed 83 risk factors in its most recent earnings report. Dyne Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Dyne Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $3.36B | -1,398.96 | -1.41% | ― | 95.29% | 98.21% | |
61 Neutral | $1.72B | -90.30 | -4.83% | ― | 23.64% | ― | |
59 Neutral | $4.70B | -7.56 | -58.28% | ― | ― | 13.71% | |
53 Neutral | $1.57B | 23.97 | 4.89% | ― | -2.20% | 77.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $6.65B | -12.64 | -83.29% | ― | ― | 0.01% | |
44 Neutral | $2.63B | -39.88 | -7.70% | ― | 157.97% | 86.11% |
* Healthcare Sector Average
DYN
Dyne Therapeutics
25.97
14.38
124.07%
SRPT
Sarepta Therapeutics
16.39
0.13
0.80%
COGT
Cogent Biosciences
42.84
31.87
290.52%
ARQT
Arcutis Biotherapeutics
26.03
10.67
69.47%
BEAM
Beam Therapeutics
28.35
10.05
54.92%
IMCR
Immunocore Holdings
33.24
1.14
3.55%
Dyne Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Dyne Therapeutics Upsized Equity Offering Strengthens Cash Runway
Positive
Jul 22, 2026
On July 21, 2026, Dyne Therapeutics priced an upsized underwritten public offering of 18,300,000 shares of common stock at $20.50 per share, with gross proceeds expected to be about $375.2 million and net proceeds estimated at $352.1 million. The ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Dyne Therapeutics Advances DYNE-251 With FDA Priority Review
Positive
Jul 20, 2026
On July 20, 2026, Dyne Therapeutics, Inc. announced that the U.S. Food and Drug Administration has accepted for review its biologics license application for zeleciment rostudirsen (DYNE-251) to treat individuals with Duchenne muscular dystrophy am...
Executive/Board Changes
Dyne Therapeutics Names Barry Greene Independent Board Director
Positive
Jun 22, 2026
On June 22, 2026, Dyne Therapeutics, Inc. appointed Barry E. Greene as a Class I independent director to its board, with a term extending until the 2027 Annual Meeting of Stockholders and continuation subject to standard conditions such as death, ...
Business Operations and StrategyPrivate Placements and Financing
Dyne Therapeutics Expands Hercules Debt Facility for Flexibility
Positive
Jun 17, 2026
On June 16, 2026, Dyne Therapeutics entered into a second amendment to its loan and security agreement with Hercules Capital and other lenders, expanding its debt facility to up to $400 million and relaxing certain financial covenants. The amendme...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Dyne Therapeutics Expands Share Authorization After Stockholder Approvals
Positive
Jun 8, 2026
On June 5, 2026, Dyne Therapeutics, Inc. held its 2026 annual meeting of stockholders, where shareholders elected David Lubner, Brian Posner and Jason Rhodes as Class III directors for terms expiring at the 2029 annual meeting. Investors also appr...
Business Operations and StrategyProduct-Related Announcements
Dyne Fully Enrolls ACHIEVE Trial for DM1 Therapy
Positive
Jun 3, 2026
On June 3, 2026, Dyne Therapeutics announced it has fully enrolled 71 participants in the registrational expansion cohort of its global Phase 1/2 ACHIEVE trial of zeleciment basivarsen in myotonic dystrophy type 1. The trial, which selected a regi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.